Etonitazene 5-acetyl analogue (Etoacetazene, 5-acetyldesnitroetonitazene) is a benzimidazole derivative with opioid effects, first developed in the 1950s as part of the research that led to better-known compounds such as etonitazene.

It is an analogue of etonitazene where the 5-nitro (NO2) group has been replaced by an acetyl (COCH3) group.

[1][2] It is described as having "reduced but still significant" potency compared to etonitazene itself.

[3] This compound was also tested as part of a series of cannabinoid receptor 2 agonists, and was found to be active though with fairly low potency of 960 nM at CB2, and negligible activity at CB1.

This analgesic-related article is a stub.